Andy Lewis appointed as Secretary of Controlled Release Society
11 Dec 2024 //
PRESS RELEASE
Quotient Sciences Issues Inaugural ESG Report
11 Dec 2024 //
PRESS RELEASE
Quotient Sciences Wins 2024 Fierce CRO Awards Category
11 Dec 2024 //
PRESS RELEASE
Quotient, Nanomerics Launch OC134 SUNLIGHT Study
11 Dec 2024 //
PRESS RELEASE
Quotient Sciences Offers New Preclinical Development Service
21 Nov 2024 //
PRESS RELEASE
Quotient Sciences Installs Centillion’s GMP Biofoundry-in-a-Box
15 Nov 2024 //
PRESS RELEASE
Quotient Recognized as a Finalist in the 2024 Fierce CRO Awards
05 Nov 2024 //
PRESS RELEASE
Thierry Van Nieuwenhove Shares Insights On Emerging Trends In CDMO
28 Oct 2024 //
PRESS RELEASE
Quotient & Medicines Announce First Dose Long-Acting Injectable
28 Oct 2024 //
PRESS RELEASE
Dr. Andy Lewis Joins Advisory Board of RSC Pharmaceutics Journal
18 Sep 2024 //
PRESS RELEASE
Quotient And Vasa Begin Human Trials Of VS-041 For Novel Heart Failure Therapy
11 Sep 2024 //
PRESS RELEASE
Quotient Sciences Wins 2024 CRO Leadership Awards
05 Jun 2024 //
PRESS RELEASE
Quotient Sciences Announces New Facility Leadership in Philadelphia, PA
05 Jun 2024 //
PRESS RELEASE
Unlocking True Partnerships: Beyond Science In Outsourcing Formulation Development
04 Jun 2024 //
PRESS RELEASE
Rare Disease Insights Orphan Pediatric Drug Development Collaboration
28 May 2024 //
PRESS RELEASE
Highlights from CPHI North America 2024: Round-up by Life Sciences Knowledge Hub
24 May 2024 //
PRESS RELEASE
Quotient Sciences and Ensysce Biosciences Continue Collaboration PF614-MPAR-102
20 May 2024 //
PRESS RELEASE
Pharmaceutical Outsourcing Roundtable: Pediatric Dosage Forms with Nazim Kanji
01 May 2024 //
PRESS RELEASE
Quotient`s Lewis Wins 2024 CRS Distinguished Service Award
01 May 2024 //
PRESS RELEASE
Outsourcing Pharma interview with Dr. Vanessa Zann
04 Apr 2024 //
PRESS RELEASE
DCAT Interview Life Sciences Hub`s Thierry Van Nieuwenhove
03 Apr 2024 //
PRESS RELEASE
Quotient Sciences Strengthens Its Top Team with Three New Appointments
18 Mar 2024 //
PR NEWSWIRE
Quotient Sciences Wins 2024 CRO Leadership Awards
01 Mar 2024 //
PRESS RELEASE
Quotient Sciences supports YourChoice Therapeutics with Phase I trial of novel hormone-free male birth control pill
13 Dec 2023 //
PRESS RELEASE
Quotient Sciences supports Medivir with updated formulation of fostrox
27 Nov 2023 //
PRESS RELEASE
Quotient Sciences Recognized in the Pharma Innovation Awards 2023
11 Nov 2023 //
PRESS RELEASE
Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO
17 Oct 2023 //
PR NEWSWIRE
Quotient Sciences Announces Successful US FDA Inspection of Alnwick, UK Facility
06 Oct 2023 //
PR NEWSWIRE
Manufacturing Chemist: Paul Quigley on overcoming bio/pharmaceutical production hurdles
02 Oct 2023 //
MANUFACTURING CHEMIST
European Pharmaceutical Manufacturer: Catherine Wilkes on Achieving HPAPI Manufacturing Success
25 Sep 2023 //
PHARMACEUTICAL MANUFACTURER
Evecxia & Quotient Sciences Complete Ph I Milestone for New Depression Treatment
21 Sep 2023 //
PR NEWSWIRE
Contract Pharma: Stephen McQuaker on HPAPI Manufacturing Trends
13 Sep 2023 //
CONTRACT PHARMA
Integrated development strategies for drug product optimisation
02 Aug 2023 //
IPT ONLINE
Quotient Sciences Presents at APS Basic Biopharmaceutics Workshop
08 Jun 2023 //
PRESS RELEASE
Quotient Sciences Wins Multiple Categories In 2023 CDMO Leadership Awards
30 Mar 2023 //
OUTSOURCE PHARMA
Quotient Sciences Announces Significant Growth in Workforce at Alnwick, UK, Facility
18 Mar 2023 //
B DAILY
Dr. Dolly Jacob: Solubility & Bioavailability
17 Mar 2023 //
DRUG DEVLOPMENT
Dr. Vanessa Zann: Pharmaceutical Technology Contribution
10 Mar 2023 //
NEPIC
Quotient Sciences Contributes to Clinical Pharmacology in Drug Development article, "A Phase 1 Study of Savolitinib"
19 Feb 2023 //
PRESS RELEASE
Quotient Sciences Expands Formulation Development Capabilities
09 Feb 2023 //
PR NEWSWIRE
Ensysce Biosciences` PF614-MPAR Enters Final Stage of Phase 1 Study
25 Jan 2023 //
PRESS RELEASE
John McDermott contributes to roundtable article with Drug Development & Delivery
19 Jan 2023 //
PRESS RELEASE
Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A
20 Dec 2022 //
ACCESSWIRE
Quotient Sciences to Host Ribbon Cutting at New Drug Substance Facility
08 Dec 2022 //
CONTRACTPHARMA
Quotient Sciences Partners with Emplicure to Manufacture and Study EMPLI03
29 Nov 2022 //
PR NEWSWIRE
Oxilio announces start of its first clinical trial with OXL001
07 Nov 2022 //
BIOPARTNER
Quotient Sciences Completes Major Expansion of Drug Substance Manufacturing Facility
19 Oct 2022 //
PR NEWSWIRE
Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development Program
29 Sep 2022 //
PR NEWSWIRE
Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics® Programs
22 Sep 2022 //
PRESS RELEASE
Ensysce & Quotient Announce a Partnership on the Testing of Ensysce`s PF614-MPAR
31 Aug 2022 //
PRESS LELEASE
South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022
25 Aug 2022 //
PRNEWSWIRE
South Rampart Pharma Appoints Josh Blacher as Chief Financial Officer
16 Aug 2022 //
PRNEWSWIRE
Quotient Limited Further Strengthens Scientific and Medical Synergies
21 Mar 2022 //
GLOBENEWSWIRE
Quotient Sciences SME comments solubility & bioavailability challenges Drug Devp
20 Mar 2022 //
PRESS RELEASE